Biosimilars Rheumatology Roundup for January 2023—Podcast Edition

On this episode of Not So Different, we reminisced about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.

Show notes

US Welcomes First Adalimumab Biosimilar, Amjevita

https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita

Canada Approves High-Concentration Humira Biosimilar

https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar

Celltrion Submits BLA for Infliximab Biobetter

https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter

FDA Accepts BLA for Alvotech Ustekinumab Biosimilar

https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar

Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study

https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study

China's NMPA Approves Tocilizumab Biosimilar

https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar

US Welcomes First Adalimumab Biosimilar, Amjevita

https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita

Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?

https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar-

Phase 1 Trial for Alvotech Golimumab Biosimilar Begins

https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins

Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis

https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis